Jens Lindberg
Medivir comments on orphan drug designation and progress in partnerships
At the end of last week, Medivir's drug candidate MIV-711 was granted Orphan Drug Designation by the FDA for the treatment of the rare...
Medivir CEO: "We have created interest among the best investigators and hospitals to want to participate in the Phase IIb study"
Medivir's Q4 report summarizes the major progress in the development...
Medivir's Phase Ib/IIa study successfully completed
Medivir has now completed the Phase Ib/IIa study evaluating...
Q2 saw continued progress for Medivir in advanced liver cancer
Medivir presented greatly improved results for patients with...
Medivir optimizes study design after meeting with FDA
Medivir has had another meeting with the FDA...
Medivir continues to accelerate development with fostrox
Medivir's recently published annual report for 2023 focuses primarily on...
Medivir sees lasting clinical benefit with fostrox
Medivir, whose ongoing rights issue ends today, the 21st...
Medivir checks off two steps ahead of Phase IIb
Medivir, which is currently in the process of issuing shares, has made progress in a short time...
Medivir on intensified partnership discussions and issuance
Medivir is conducting a rights issue between December 7 and 21...
Medivir aims for accelerated FDA approval through issuance
Hepatocellular carcinoma is the most common form of primary...
Medivir's CEO comments on the ongoing rights issue
Medivir is currently conducting a rights issue of up...
Medivir's CEO comments on updated clinical data
Medivir continues to make progress with the drug candidate fostrox...